ALK and non-small cell lung carcinoma: In addition, only 2 patients in cohort A of the third-line group were treated with lorlatinib, the only ALKi to date, which was validated prospectively and is indicated for third line in patients with ALK-positive NSCLC.14 Both of these treatment choices are expected considering the timeframe of this study, mostly during a period when crizotinib was the only first-line ALKi approved and lorlatinib was not available.